Highlights
ASX: ANP       ANTISENSE THERAPEUTICS LIMITED
Last Price Today's Change   Day's Range   Trading Volume
0.082   +0.007 (9.33%)  0.073 - 0.082  842,556

Overview

 
Avg Volume (4 weeks):927,884
4 Weeks Range:0.073 - 0.11
4 Weeks Price Volatility (%):
24.32%
52 Weeks Range:0.073 - 0.35
52 Weeks Price Volatility (%):
3.25%
Average Price Target:-

Headlines



No recent Headlines for this stock.


Business Background

Antisense Therapeutics Limited (ANP) is an Australia-based pharmaceutical drug discovery and development company. The Company is engaged in the research and development of antisense pharmaceuticals. The Company's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly, diabetic retinopathy and diabetic nephropathy. The Company's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The Company completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The Company's product candidate, ATL1101, is an antisense inhibitor of insulin like growth factor 1 receptor (IGF-Ir). It is developing ATL1101 for the treatment of prostate cancer. It is also developing ATL1102 as an inhaled treatment for asthma.

  Be the first to like this.
 


APPS
I3 Messenger
Individual or Group chat with anyone on I3investor
 
 

719  737  616  1589 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 HRL 0.160.00 
 XST 0.0020.00 
 SYA 0.155+0.005 
 TEM 0.096+0.004 
 PCL 0.0060.00 
 AO1 0.0020.00 
 IMU 0.195+0.015 
 LKE 0.76-0.025 
 NWE 0.0440.00 
 PLS 2.24-0.05